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Abstract
Background: Active surveillance (AS) is commonly used for men with low-risk prostate
cancer (PCa). When life expectancy becomes too short for curative treatment to be
beneficial, a change from AS to watchful waiting (WW) follows. Little is known about
this change since it is rarely documented in medical records.
Objective: To model transition from AS to WW and how this is affected by age and
comorbidity among men with very low-risk PCa.
Design, setting, and participants: National population-based healthcare registers were
used for analysis.
Outcome measurements and statistical analysis: Using data on PCa characteristics, age,
and comorbidity, a state transition model was created to estimate the probability of
changes between predeﬁned treatments to estimate transition from AS to WW.
Results and limitations: Our estimates indicate that 48% of men with very low-risk PCa
starting AS eventually changed to WW over a life course. This proportion increased with
age at time of AS initiation. Within 10 yr from start of AS, 10% of men aged 55 yr and 50%
of men aged 70 yr with no comorbidity at initiation changed to WW. Our prevalence
simulation suggests that the number of men on WW who were previously on AS will
eventually stabilise after 30 yr. A limitation is the limited information from clinical
follow-up visits (eg, repeat biopsies).
Conclusions: We estimated that changes from AS to WW become common among men
with very low-risk PCa who are elderly. This potential change to WW should be
discussed with men starting on AS. Moreover, our estimates may help in planning
health care resources allocated to men on AS, as the transition to WW is associated with
lower demands on outpatient resources.
Patient summary: Changes from active surveillance to watchful waiting will become
more common among men with very low-risk prostate cancer. These observations
suggest that patients need to be informed about this potential change before they start
on active surveillance.
# 2016 European Association of Urology. Published by Elsevier B.V. This is an openhe access article under ty These authors contribute
* Corresponding author. C
London, Bermondsey Wing
E-mail address: mieke.vanh
Please cite this article in press as: Van Hemelrijck M, et al. Qua
Waiting Among Men with Very Low-risk Prostate Cancer. Eur Ur
http://dx.doi.org/10.1016/j.eururo.2016.10.031
0302-2838/# 2016 European Association of Urology. Published by Elsevier
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).d equally to this work.
ancer Epidemiology Group, Division of Cancer Studies, King’s College
, Guy’s Hospital, London SE1 9RT, UK. Tel. +44 20 71887904.
emelrijck@kcl.ac.uk (M. Van Hemelrijck).
ntifying the Transition from Active Surveillance to Watchful
ol (2016), http://dx.doi.org/10.1016/j.eururo.2016.10.031
 B.V. This is an open access article under the CC
E U R O P E A N U R O L O G Y X X X ( 2 0 1 6 ) X X X – X X X2
EURURO-7107; No. of Pages 81. Introduction
Active surveillance (AS) is a common management strategy
for men with low-risk prostate cancer (PCa). AS, with the
intention to start curative treatment at the time of
progression, may preserve some of the benefits of screening
by minimising the harm caused by overtreatment of
indolent cancer [1–6].
AS has been used for management of men with low-risk
PCa for more than a decade [6]. AS ends when curative
treatment is started, when changing to watchful waiting
(WW), or when death occurs [2–6]. WW, also called
symptom-guided treatment, is a management option for
men with low-risk PCa who have a limited life expectancy
and for whom curative treatment at the time of progression
is not deemed to be beneficial. Men on WW typically start
on androgen deprivation therapy (ADT) when symptomatic
progression occurs [5,7].
The PCa among a large proportion of men on AS will not
progress, and these men will thus remain on AS for a long
period of time. Their life expectancy will at some point
become so short that curative treatment is no longer
indicated, leaving WW as the remaining option. This change
to WW has an impact on health care resource allocation, as
it is associated with less intense follow-up (eg, no more
biopsies). However, the precise time point for this change is
rarely defined and documented in medical records. Only a
few studies to date have investigated the change from AS to
WW, as most studies on AS focus on the change to curative
treatment [8,2,9].
The aim of the current study was to assess the change
from AS to WW among men with very low-risk PCa. We
adopted a state transition model [10] using comprehensive
data on cancer characteristics and comorbidity to estimate
the proportion of men who change from AS to WW and
when this occurs [11,12]. We also investigated how this
change from AS to WW is affected by age and comorbidity.
2. Patients and methods
2.1. Study population and data collection
In 2012, the National Prostate Cancer Register (NPCR) of Sweden was
record linked to a number of other population-based registers using the
Swedish personal identity number [11,12]. The linkage was updated in
2014. The NPCR became nationwide in 1998 and captures more than 98%
of all newly diagnosed PCa compared to the Swedish Cancer Registry.
NPCR keeps detailed information on tumour characteristics and primary
treatment at the time of diagnosis. Combining data from the National
Patient Register and the National Prescribed Drug Register regarding
subsequent treatment changes with the NPCR and other health care
registers and demographic databases resulted in PCBaSeTraject, which is
the basis for this study [12]. To assess the burden of concomitant disease,
all changes in Charlson comorbidity index (CCI) [16] during the course of
follow-up were retrieved from the National Patient Register and the
Swedish Cancer Register. The date of prostate biopsy as registered in
the National Patient Register was used as an indication of ongoing AS.
More speciﬁcally, WW and AS were both registered in the NPCR as
deferred treatment up to 2007, after which they were distinguished.
Their deﬁnitions are consistent with international guidelines [2–6]. AS isPlease cite this article in press as: Van Hemelrijck M, et al. Qua
Waiting Among Men with Very Low-risk Prostate Cancer. Eur Urdeﬁned as a strategy in which the man is followed closely and curative
treatment is initiated if there is evidence of disease progression. By
contrast, WW is usually performed for men with a limited life
expectancy, and ADT is initiated if symptomatic progression occurs [14].
We selected men with very low-risk PCa who started AS. Very low-
risk PCa was deﬁned as Gleason score 6 with prostate-speciﬁc antigen
(PSA) 10 ng/ml, prostate volume <90 cm3, PSA density <0.2, 6–12 core
biopsies performed, T1c or T2, positive cores 33%, and cancer length
6 mm as deﬁned by Loeb et al [13] in a previous PCBaSe study. We
added an additional age restriction (age 40–75 yr) in accordance with
the Swedish recommendation for AS [14]. Biopsy-related information
was not available for all men, and therefore we used multiple
imputation based on chained equations [15] to create ﬁve imputation
data sets in which it was possible to deﬁne whether the above criteria
were fulﬁlled or not. Data were missing for cancer length in biopsies
(51%), percentage positive cores (40%), and prostate volume (37%);
complete data were available for 46% of men. The imputation was based
on all data presented in Table 1 as well as time-to-event data.
Furthermore, since the NPCR did not make a distinction between WW
and AS before 2007, this group of men (n = 856) are classiﬁed as
unknown deferred treatment (DT). To determine whether these men
were on AS or WW, we treated this as a missing data problem
(Supplementary material). Finally, men on WW as their primary
treatment were included in the study to facilitate the estimation of
changes from AS to WW.
To enhance the precision of our estimates, we used the above
methods after inclusion of men with low-risk PCa (Gleason score 6,
stage T1c/T2, PSA <10 ng/ml) who did not fulﬁl the above-mentioned
deﬁnition of very low-risk PCa. In Sweden, a large proportion of men
with low-risk PCa are also on AS. For instance, 74% of men with low-risk,
but not very low-risk, PCa were assigned to AS in 2014 [8]. More
speciﬁcally, we used information for men with low-risk PCa to obtain
additional information on treatment and comorbidity changes, which
was then included in our models. Detailed results for men with low-risk
PCa who did not fulﬁl the deﬁnition of very low-risk PCa are presented in
the Supplementary material.
The Research Ethics Board at Umea˚ University approved this study.
2.2. Statistical methods
The change from AS to WW involves a competing risks problem. In
addition to the two competing risks described above (ie, the change to
curative treatment [radical prostatectomy or radiotherapy] or death), we
also considered AS failure as a competing risk. AS failure was deﬁned as
initiation of ADT for men on AS without any signs of disease progression.
Since the change from AS to WW was not documented in PCBaSe, we
could not calculate cumulative incidence proportions as deﬁned by
Kalbﬂeisch and Prentice [16] nor could we use standard imputation
techniques.
We therefore investigated changes from AS using a state transition
model [10,17]. We estimated the probability of treatment changes
(transition probabilities) between predeﬁned treatments (states), as
illustrated by the arrows (transitions) and circles (states) in Fig. 1. Each
patient was followed from the initial state (yellow boxes) until ending up
in an absorbing state (orange boxes). All state transition models were
developed in accordance with the good practice guidelines of the ISPOR
Modeling Task Force and the Society for Medical Decision Making [18].
Figure 1A shows the intended study. However, as no data are
available to directly investigate the change from AS to WW, we also
included men on WW as a primary treatment in our analyses (Figure 1B).
Apart from transitions to curative treatment, WW, and AS failure, we also
added the possibility of a transition from AS to ADT (AS ! WW ! ADT).
As our main aim was to study the transition from AS to WW, secondary
transitions (eg, radical prostatectomy ! death) are not shown inntifying the Transition from Active Surveillance to Watchful
ol (2016), http://dx.doi.org/10.1016/j.eururo.2016.10.031
Table 1 – Baseline characteristics at time of prostate cancer diagnosis by initial treatment category for men in the study population in
PCBaSe (data taken from imputation data set 1)
AS (n = 5963) WW (n = 537) DT (n = 856) All (n = 7356)
Median age, yr (IQR) 65.3 (61.0–68.8) 72.1 (68.4–75.6) 69.1 (63.5–72.2)) 66.0 (61.6–69.8)
Age, n (%)
55 yr 364 (6.1) 6 (1.1) 41 (4.8) 411 (5.6)
56–60 yr 873 (14.6) 22 (4.1) 78 (9.1) 973 (13.2)
61–65 yr 1627 (27.3) 55 (10.2) 149 (17.4) 1831 (24.9)
66–70 yr 2095 (35.1) 112 (20.9) 208 (24.3) 2415 (32.8)
71–80 yr 1004 (16.8) 280 (52.1) 380 (44.4) 1664 (22.6)
81 yr 62 (11.5) 62 (0.8)
Year of diagnosis, n (%)
1992–1997 27 (3.2) 27 (0.4)
1998–2004 157 (2.6) 40 (7.4) 388 (45.3) 585 (8.0)
2005–2008 1037 (17.4) 151 (28.1) 359 (41.9) 1547 (21.0)
2009–2011 1977 (33.2) 208 (38.7) 47 (5.5) 2232 (30.3)
2012–2014 2792 (46.8) 138 (25.7) 35 (4.1) 2965 (40.3)
CCI, n (%)
0 4414 (74.0) 368 (68.5) 692 (80.8) 5474 (74.4)
1 754 (12.6) 94 (17.5) 86 (10.0) 934 (12.7)
2 421 (7.1) 40 (7.4) 56 (6.5) 517 (7.0)
3+ 374 (6.3) 35 (6.5) 22 (2.6) 431 (5.9)
T stage, n (%)
T1c 5213 (87.4) 412 (76.7) 662 (77.3) 6287 (85.5)
T2 750 (12.6) 125 (23.3) 194 (22.7) 1069 (14.5)
N stage, n (%)
N0 674 (11.3) 38 (7.1) 19 (2.2) 731 (9.9)
Nx 5289 (88.7) 499 (92.9) 837 (97.8) 6625 (90.1)
Gleason score, n (%)
2–6 5958 (99.9) 536 (99.8) 794 (92.8) 7288 (99.1)
Missing a 5 (0.1) 1 (0.2) 62 (7.2) 68 (0.9)
PSA, n (%)
0–3.0 ng/ml 546 (9.2) 31 (5.8) 91 (10.6) 668 (9.1)
3.1–6.0 ng/ml 3813 (63.9) 281 (52.3) 441 (51.5) 4535 (61.7)
6.1–10.0 ng/ml 1604 (26.9) 225 (41.9) 324 (37.9) 2153 (29.3)
Median LCBC, mm (IQR) 1.5 (1.0–3.0) 2.0 (1.0–3.5) 1.5 (1.0–2.6) 1.6 (1.0–3.0)
Data missing, n (%) 1289 (21.6) 200 (37.2) 773 (90.3) 2262 (30.8)
Median PV, cm3 (IQR) 42 (34–54) 48 (37–58) 45 (35–59) 43 (34–55)
Data missing, n (%) 647 (10.9) 121 (22.5) 767 (89.6) 1535 (20.9)
Median PPC (IQR) 0.10 (0.10–0.20) 0.17 (0.10–0.20) 0.10 (0.10–0.17) 0.10 (0.10–0.20)
Data missing, n (%) 493 (8.3) 106 (19.7) 760 (88.8) 1359 (18.5)
Mode of detection, n (%)
Screening 3648 (61.2) 219 (40.8) 303 (35.4) 4170 (56.7)
LUTS 1555 (26.1) 213 (39.7) 226 (26.4) 1994 (27.1)
Other symptoms 648 (10.9) 96 (17.9) 232 (27.1) 976 (13.3)
Unknown 112 (1.9) 9 (1.7) 95 (11.1) 216 (2.9)
AS = active surveillance; WW = watchful waiting; DT = unknown deferred treatment; CCI = Charlson comorbidity index; LCBC = length of cancer in biopsy
cores; PPC = proportion of cores with cancer; PV = prostate volume; LUTS = lower urinary tract symptoms.
a In the case of missing Gleason score, all men had World Health Organisation grade 1.
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Fig. 1 – State transition model defining transitions (arrows) between states (circles): active surveillance (AS) to curative treatment (radical
prostatectomy/radiotherapy, RP/RT), death, AS failure, or watchful waiting (WW) and androgen deprivation therapy (ADT). Red circles represent
transient stages and orange circles represent absorbing states. The light orange circles represent additional information gathered to facilitate the
estimation of transition probabilities (biopsy and Charlson comorbidity index [CCI]).
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study.
The basic assumption for all our modelling is that the age-speciﬁc
transition rates from WW to ADT are similar for men starting on WW
(WW ! ADT) as for those starting on AS and those changing to ADT via
WW (AS ! WW ! ADT). In men starting on WW, the transition to ADT is
observable in the data, and therefore the transition rate for WW ! ADT
can be estimated directly as shown in Figure 1B (arrow II). Moreover,
since the start of ADT in the event chain AS ! WW ! ADT (arrow III) can
be observed, it is also possible to indirectly estimate the transition rate
for AS ! WW (arrow I) using the above basic assumption (Supplemen-
tary material).
2.2.1. State transition model
Our state transition model used discrete time steps of 4 wk. During each
time step, a man either remained in his state or moved to a new state.
Each man was followed from the date of diagnosis or January 1, 2006,
whichever came last (left truncation), until reaching an absorbing state
or the end of follow-up (December 31, 2014), whichever came ﬁrst.
Using the date January 1, 2006 as study entry allowed for a 6-mo run-in
period, as ADT treatments were identiﬁed from the Swedish Prescribed
Drug Register, which only started on July 1, 2005.
Since the person-time on AS is unknown, the probability of directly
observable transitions such as death and curative treatment cannot be
estimated via logistic regression. We therefore created a single large
model incorporating all transitions in Figure 1B and their relation to0  5  10  15  2
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and CCI. The regression coefﬁcients were ﬁtted using maximum
likelihood methods. The Supplementary material provides further
details on the model speciﬁcations.
In this model we also included additional indirect information as
follows. A biopsy was considered as an indication for remaining on AS,
whereas a long period without biopsies increased the likelihood of a
transition to WW. Initiation of curative treatment indicated that a man
had been on AS until that point in time. Initiation of ADT was considered
as evidence of a previous transition to WW in the model. However, there
were exceptions: When a young man with low comorbidity (CCI 0)
received ADT shortly after PCa diagnosis, this was deﬁned as an AS
failure (Supplementary Table 2). A separate state-transition probability
was created for this situation (Supplementary material) [2–6].
2.2.2. Estimations
To visualise the ﬁtted model in terms of the timing and occurrence of
state transitions in accordance with Figure 1B, we calculated estimations
for men with speciﬁc age and CCI scores [10]. First, we assessed the
sensitivity of our assumption of similar transition rates for AS ! WW
and AS ! WW ! ADT. We therefore estimated the cumulative incidence
of AS ! WW transitions based on ﬁve variations of our assumption using
relative transition rates of 50%, 80%, 100%, 150%, and 200%, but noticed
very little difference. For instance, for men aged 55 yr, the proportion of
men who switched to WW within 10 yr was 15%, 13%, 13%, 11%, and 10%,
respectively, for the ﬁve transition rates. Similarly, for men aged 70 yr,0  25 0  5  10 
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results presented are therefore based on equal rates (100%).
In the main analysis, we estimated transitions for two different
scenarios in which all men eventually transitioned from AS to another
state (Fig. 1B). In the ﬁrst scenario we focused on men aged 55, 60, 65, or
70 yr with CCI = 0 starting on AS. More details on the methods used for
these estimations can be found in the Supplementary material. For the
second scenario, we performed estimations for a theoretical cohort
created using an annual inﬂow of men on AS selected as annual
bootstrapped samples of 1000 men from the pool of men on AS in
NPCR diagnosed with very low-risk PCa between 2010 and 2014. The
annual inﬂow of men was continued for a period of 40 yr. In both
scenarios, CCI was updated according to an independent model, as
described below.
2.2.3. CCI model
A model for CCI development over time was required for the estimations
described above. In brief, this was achieved by estimating whether a
change in CCI took place or not for each time step. If a change in CCI had
occurred, the size of this change was estimated from a Poisson model,
together with a separate model handling CCI changes 6. Details of this
method can be found elsewhere [19].
3. Results
A total of 17 783 men with low-risk PCa on AS, WW, or DT
were recorded in NPCR between 1992 and 2014 (Supple-
mentary Table 1). After imputation of missing data, we
identified 7278 men with very low-risk PCa (median over
five imputation data sets with size ranging from 7169
to 7388).Pr
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PCa diagnosis for imputation data set 1 by initial treatment
(AS, WW, DT). The number of men with very low-risk PCa on
AS increased during later time periods. Men on AS were
younger (mean age 65 yr) than men on WW (mean age
72 yr). The mean age in the DT group was 67 yr.
Figure 2 shows the estimated proportion of men
(CCI = 0 at time of PCa diagnosis) who remained on AS,
failed AS, changed to radical treatment, changed to WW, or
died as a first event following AS over time. Older age at
start of AS was associated with a greater proportion of men
transitioning WW, whereas younger age was associated
with a greater proportion of men undergoing radical
treatment. For instance, within 10 yr from AS initiation,
10% of men aged 55 yr with CCI = 0 at start of follow-up
were estimated to transition to WW, compared to 50% of
men aged 70 yr.
Figure 3 shows the estimated prevalence of men who
either remained on AS or transitioned to WW over a period
of 40 yr according to our estimation model based on an
annual inflow of 1000 men with very low-risk PCa on AS.
The prevalence of men on WW increased slowly during the
first years, with the highest rate of prevalence change
occurring during 10–20 yr, and stabilised after 30 yr. The
age-specific prevalence simulations indicate that preva-
lence change occurred less frequently for younger men.
Tables 2 and 3 further quantify these prevalence changes
and show that the time on AS decreases with age, whereas
the proportion of men changing to WW increases with age.
Overall, men with very low-risk PCa remained on AS forTime (yr) 
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Table 3 – Median time on WW and proportion of patients reaching absorbing states as estimated from the prevalence models based on
annual inflow of 1000 patients/yr in each stratum
Age at prostate cancer diagnosis
53–57 yr 58–62 yr 63–67 yr 68–72 yr All
Median time on WW, yr (IQR) 12.6
(5.9–21.5)
10.3
(5.0–17.2)
8.8
(4.2–14.5)
8.0
(3.8–13.0)
8.7
(4.2–14.4)
Patients reaching ADT as second event (%) 28.7 27.9 27.1% 26.5 26.9
Patients reaching death as ﬁrst event (%) 71.3 72.1 72.9% 73.5 73.1
ADT = androgen deprivation therapy; IQR = interquartile range; WW = watchful waiting.
Table 2 – Median time on AS and proportion transitioning to WW and absorbing states as estimated from the prevalence models based on
annual inflow of 1000 patients/yr in each stratum
Age at prostate cancer diagnosis
53–57 yr 58–62 yr 63–67 yr 68–72 yr All
Median time on AS, yr (IQR) 5.4
(2.2–10.7)
5.3
(2.2–10.4)
5.1
(2.1–9.7)
4.6
(2.1–7.7)
4.7
(2.0–8.7)
Patients reaching WW as ﬁrst event (%) 29.2 34.4 45.2 62.3 48.3
Patients reaching CT as ﬁrst event 61.0 54.3 42.2 24.4 39.6
Patients AS failure as ﬁrst event (%) 2.2 2.1 2.0 2.2 2.3
Patients reaching death as ﬁrst event (%) 7.6 9.2 10.6 11.1 9.8
AS = active surveillance; CT = curative treatment; IQR = interquartile range; WW = watchful waiting.
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EURURO-7107; No. of Pages 8approximately 5 yr (median), and 48% changed to WW over
a life course (approximated by 40 yr in our simulations;
Table 2). Once a transition to WW had occurred, these men
remained in this state for a median time of 9 yr (Table 3).
4. Discussion
We evaluated the change from AS to WW for men with very
low-risk PCa using a large, population-based representative
sample of men with very low-risk PCa in Sweden. Our
estimations indicate that almost half of men with very low-
risk PCa starting AS will eventually change to WW. This
proportion increased with age and with comorbidity at time
of AS initiation. Overall, the estimated median time on AS
was 5 yr. Our prevalence simulation suggests that the
number of men on WW who were previously on AS will
eventually stabilise after 30 yr.
A few studies have investigated the change from AS to
WW [8,2,9]. For instance, van As and colleagues [9] followed
326 men on AS for a median time of 22 mo and observed
that 20% had deferred radical treatment, 5% changed to
WW, 2% died of other causes, and 73% remained on AS. Klotz
and colleagues [20] followed 993 men over a median time of
6 yr, and observed that 267 men went on to curative
intervention and 15 died; no information on the change to
WW was available. There are currently limited guidelines
[21,22] on the change from AS to WW. The treatment
pathways for men with very low-risk PCa also vary by
country and are managed differently in various health care
systems. In light of the increasing use of AS as primary
management for men with low-risk PCa in Europe and the
USA [1] (Loeb et al, unpublished data), there is a need forPlease cite this article in press as: Van Hemelrijck M, et al. Qua
Waiting Among Men with Very Low-risk Prostate Cancer. Eur Urguidelines to include criteria for the change from AS to WW.
In daily clinical practise, follow-up during AS is probably not
as intense as recommended by the guidelines, and the
change from AS to WW may also not be clearly defined,
either for the patient or for the urologist, as indicated by two
recent publications based on Surveillance, Epidemiology,
and End Results data [23,24].
Our simulation, which aimed to assess the overall change
from AS to WW, suggests that in the near future there will
be a rapid increase in the number of men who will transition
from AS to WW. Our models indicate that this change from
AS to WW will eventually become quite common. However,
it is important to note that in clinical practice the actual
transition to WW for an individual patient is not a
probabilistic entity, but is rather based on age, CCI, the
patient’s preference, and clinical practice. Thus, our model
is not intended as a tool for decision-making at an
individual level. Although the vast majority of men who
change from AS to WW will do so because of old age, some
men change to ADT without a previous curative intervention:
they either missed the opportunity for curative treatment or
made an active choice to not undergo curative treatment.
Our model estimates support the observation that a large
proportion of men will reach the point at which a change to
curative treatment is no longer an option. As this affects the
intensity of follow-up (eg, fewer repeat biopsies), urologists
should inform patients of this change [25], preferably before
they start on AS.
The change from AS to WW not only affects patients and
clinicians but also has an economic impact. Currently,
protocols for AS [14,26,27] include frequent PSA testing,
regular repeat biopsies, and in the future probably also
repeat imaging [28]. The risk of infection after prostatentifying the Transition from Active Surveillance to Watchful
ol (2016), http://dx.doi.org/10.1016/j.eururo.2016.10.031
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EURURO-7107; No. of Pages 8biopsy is not negligible [29]. Apart from the costs related to
adverse events, there is also a potential cost linked to
imaging [30,31]. A change from AS to WW may thus reduce
health care expenditure as there will be fewer follow-up
costs (eg, biopsies and related complications, imaging). Data
on the change from AS to WW will not only help in
estimating these costs, but also affect the validity of current
health evaluations of AS effectiveness, as patients need
information on the change from AS to WW to provide
accurate patient-reported outcome measures and experi-
ence measures for AS [21].
A major strength of our study is the use of comprehen-
sive data from PCBaSeTraject, a large, nationwide, popula-
tion-based database on PCa [13]. These data were used to
assess transition rates in the models for the changes
between different treatment options. Owing to the detailed
information available, we could adjust our estimations for
comorbidities and age, resulting in high internal validity.
The models are therefore reliable. Even though our results
were based on Swedish data only, we believe that the
external validity of our study is acceptable for other
populations with similar age-related rates of change in
CCI. A limitation of our study is the scarce data on follow-up
(eg, on repeat biopsies) as these are underreported in the
Patient Register, and lack of information on the actual
change from AS to WW for individual patients. Another
limitation is that follow-up was not long enough to
investigate causes of death for men with low-risk PCa on
AS. With longer follow-up, a future study including this
information could provide insight into whether AS was an
appropriate choice and whether the change to WW was
performed at the right time. Finally, it may be a limitation
that we assumed similar transition rates for WW to ADT and
AS to ADT for men of all ages, an assumption that cannot be
verified by our data. However, we evaluated the effects of
this assumption using different rates and noted very little
differences in the results.
5. Conclusions
We estimated that changes from AS to WW become
more common in men with very low-risk PCa, especially
those who were elderly at the time of AS initiation. Our state
transition models estimated that a large proportion of
men with very low-risk PCa starting AS will change to
WW. These observations suggest that patients need to be
informed about this potential change before starting AS.
Moreover, the impact of the change to WW on allocation of
health care resources has probably been underestimated to
date (less follow-up expenditure on WW compared to AS)
and future guidelines on follow-up during AS should take
this into account.
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